Intermittent Keto and GLP-1 for Inflammation: A Synergistic Approach
The ketogenic diet (KD) has gained significant attention in recent years due to its potential benefits for weight loss, improved insulin sensitivity, and reduced chronic inflammation. Meanwhile, glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a promising treatment for obesity and metabolic diseases. In this article, we will explore the synergy between intermittent keto and GLP-1 for inflammation, including potential benefits and considerations.
What is Intermittent Keto?
Intermittent keto is a variation of the ketogenic diet that involves alternating periods of carbohydrate restriction with periods of normal eating. This approach can help promote weight loss, improve insulin sensitivity, and reduce chronic inflammation. The KD involves a high-fat, moderate-protein, and low-carbohydrate diet, which induces a metabolic state called nutritional ketosis.
What is GLP-1?
GLP-1 is a peptide hormone produced in the gut after a meal. It stimulates insulin secretion, helps maintain blood glucose homeostasis, and promotes satiety. GLP-1 receptor agonists, such as semaglutide and liraglutide, enhance insulin secretion, suppress appetite, and slow gastric emptying, facilitating weight loss.
The Synergy between Intermittent Keto and GLP-1
Several studies have demonstrated the beneficial effects of combining GLP-1 receptor agonists with the ketogenic diet for weight loss and improved metabolic health. For example, a study published in the Journal of Clinical Endocrinology and Metabolism found that individuals who underwent a ketogenic diet and received semaglutide therapy experienced a significant reduction in body weight and improved insulin sensitivity.
